Cargando…

Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bijelic, Lana, Sugarbaker, Paul H., Stuart, O. Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395133/
https://www.ncbi.nlm.nih.gov/pubmed/22811702
http://dx.doi.org/10.1155/2012/827534
_version_ 1782237938618204160
author Bijelic, Lana
Sugarbaker, Paul H.
Stuart, O. Anthony
author_facet Bijelic, Lana
Sugarbaker, Paul H.
Stuart, O. Anthony
author_sort Bijelic, Lana
collection PubMed
description Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of this study is to review our experience using melphalan for HIPEC. Pharmacologic data was obtained. Thirty four patients who underwent CRS for peritoneal metastases received melphalan for HIPEC between 2003 and 2011. The first 10 patients received 70 mg/m(2); subsequent 24 received 60 or 70 mg/m(2). The mean PCI was 21 ± 7. Twenty-eight patients (83%) had a CC score of 1 or 2. The mean length of stay was 18 ± 2 days. Nine patients (26%) had a grade 3 and 6 (17%) had grade 4 morbidity. There were no postoperative deaths. The pharmacologic analysis of plasma to peritoneal fluid levels of melphalan showed an AUC ratio of 33 while the tumor nodules to peritoneal ratio was 8. Melphalan is an acceptable agent for use in HIPEC. The morbidity of intraperitoneal melphalan at the dose of 60–70 mg/m(2) appears acceptable. Further studies comparing the effectiveness of melphalan and other HIPEC agents are needed.
format Online
Article
Text
id pubmed-3395133
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33951332012-07-18 Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients Bijelic, Lana Sugarbaker, Paul H. Stuart, O. Anthony Gastroenterol Res Pract Research Article Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents for HIPEC have not been established. Melphalan is a drug with broad activity and a favorable profile for intraperitoneal application. The purpose of this study is to review our experience using melphalan for HIPEC. Pharmacologic data was obtained. Thirty four patients who underwent CRS for peritoneal metastases received melphalan for HIPEC between 2003 and 2011. The first 10 patients received 70 mg/m(2); subsequent 24 received 60 or 70 mg/m(2). The mean PCI was 21 ± 7. Twenty-eight patients (83%) had a CC score of 1 or 2. The mean length of stay was 18 ± 2 days. Nine patients (26%) had a grade 3 and 6 (17%) had grade 4 morbidity. There were no postoperative deaths. The pharmacologic analysis of plasma to peritoneal fluid levels of melphalan showed an AUC ratio of 33 while the tumor nodules to peritoneal ratio was 8. Melphalan is an acceptable agent for use in HIPEC. The morbidity of intraperitoneal melphalan at the dose of 60–70 mg/m(2) appears acceptable. Further studies comparing the effectiveness of melphalan and other HIPEC agents are needed. Hindawi Publishing Corporation 2012 2012-07-03 /pmc/articles/PMC3395133/ /pubmed/22811702 http://dx.doi.org/10.1155/2012/827534 Text en Copyright © 2012 Lana Bijelic et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bijelic, Lana
Sugarbaker, Paul H.
Stuart, O. Anthony
Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
title Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
title_full Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
title_fullStr Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
title_full_unstemmed Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
title_short Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
title_sort hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395133/
https://www.ncbi.nlm.nih.gov/pubmed/22811702
http://dx.doi.org/10.1155/2012/827534
work_keys_str_mv AT bijeliclana hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients
AT sugarbakerpaulh hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients
AT stuartoanthony hyperthermicintraperitonealchemotherapywithmelphalanasummaryofclinicalandpharmacologicaldatain34patients